Cutera (Cutera) Long-Term Capital Lease Obligation : $9.5 Mil (As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cutera Long-Term Capital Lease Obligation?

Cutera's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $9.5 Mil.

Cutera's quarterly Long-Term Capital Lease Obligation declined from Mar. 2023 ($11.3 Mil) to Jun. 2023 ($10.6 Mil) and declined from Jun. 2023 ($10.6 Mil) to Sep. 2023 ($9.5 Mil).

Cutera's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($16.0 Mil) to Dec. 2021 ($13.5 Mil) and declined from Dec. 2021 ($13.5 Mil) to Dec. 2022 ($11.4 Mil).

Cutera Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cutera's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutera Long-Term Capital Lease Obligation Chart

Cutera Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.11

15.95

13.48

11.35

Cutera Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															12.33	11.35	11.33	10.61	9.47

Cutera (NAS:CUTR) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cutera Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cutera's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cutera (Cutera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cutera Inc (NAS:CUTR) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TJ9:Germany

Address

3240 Bayshore Boulevard, Brisbane, CA, USA, 94005

Website

https://www.cutera.com

Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.

Executives

Taylor C. Harris	director	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Stuart Drummond	officer: Interim Chief Financial Office	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Jeffrey S Jones	officer: Chief Operating Officer	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Kevin J Cameron	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Keith J Sullivan	director	C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
David H Mowry	director, officer: Chief Executive Officer	9775 TOLEDO, IRVINE CA 92618
Rohan Seth	officer: Chief Financial Officer	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Timothy J Oshea	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Juliane Park	director	C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE CA 94005
Janet D. Widmann	director	1411 E. MISSION AVENUE, SPOKANE WA 99202
J Daniel Plants	director	ONE EMBARCADERO CENTER, SUITE 1140, SAN FRANCISCO CA 94111
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Joseph E Whitters	director
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016